Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Poyatos

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Neural Networks : the Official Journal of the International Neural Network Society|November 28, 2022
EvoPruneDeepTL: An evolutionary pruning model for transfer learning based deep neural networksJavier Poyatos, Daniel Molina, Aritz D Martinez, et al.
Molecular Therapy. Nucleic Acids|September 30, 2021
Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through <i>miR-7</i> biogenesis repressionMaria Sabater-Arcis, Ariadna Bargiela, Nerea Moreno, et al.
Molecular Therapy. Nucleic Acids|February 15, 2023
CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2Javier Poyatos-García, Águeda Blázquez-Bernal, Marta Selva-Giménez, et al.
European Journal of Neurology|November 5, 2020
A study of the phenotypic variability and disease progression in Laing myopathy through the evaluation of muscle imagingNuria Muelas, Marina Frasquet, Fernando Más-Estellés, et al.
Skeletal Muscle|October 1, 2024
Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro modelJavier Poyatos-García, Patricia Soblechero-Martín, Alessandro Liquori, et al.
Scientific Reports|September 15, 2021
Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screeningPatricia Soblechero-Martín, Edurne Albiasu-Arteta, Aina Anton-Martinez, et al.
Multiple Sclerosis and Related Disorders|June 16, 2026
Tear CHI3L1 in multiple sclerosis: a non-invasive biomarker linked to disease progressionJéssica Castillo-Villalba, Raquel Gasque-Rubio, Lorena Forés-Toribio, et al.
Science Advances|October 9, 2024
AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of actionEstefanía Cerro-Herreros, Judit Núñez-Manchón, Neia Naldaiz-Gastesi, et al.
Molecular Therapy. Nucleic Acids|September 13, 2021
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophyEstefanía Cerro-Herreros, Irene González-Martínez, Nerea Moreno, et al.
Journal of Neurology|January 8, 2025
Clinical features, mutation spectrum and factors related to reaching molecular diagnosis in a cohort of patients with distal myopathiesNuria Muelas, Lidón Carretero-Vilarroig, Pilar Martí, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Neural Networks : the Official Journal of the International Neural Network Society|November 28, 2022
EvoPruneDeepTL: An evolutionary pruning model for transfer learning based deep neural networksJavier Poyatos, Daniel Molina, Aritz D Martinez, et al.
Molecular Therapy. Nucleic Acids|September 30, 2021
Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through <i>miR-7</i> biogenesis repressionMaria Sabater-Arcis, Ariadna Bargiela, Nerea Moreno, et al.
Molecular Therapy. Nucleic Acids|February 15, 2023
CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2Javier Poyatos-García, Águeda Blázquez-Bernal, Marta Selva-Giménez, et al.
European Journal of Neurology|November 5, 2020
A study of the phenotypic variability and disease progression in Laing myopathy through the evaluation of muscle imagingNuria Muelas, Marina Frasquet, Fernando Más-Estellés, et al.
Skeletal Muscle|October 1, 2024
Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro modelJavier Poyatos-García, Patricia Soblechero-Martín, Alessandro Liquori, et al.
Scientific Reports|September 15, 2021
Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screeningPatricia Soblechero-Martín, Edurne Albiasu-Arteta, Aina Anton-Martinez, et al.
Multiple Sclerosis and Related Disorders|June 16, 2026
Tear CHI3L1 in multiple sclerosis: a non-invasive biomarker linked to disease progressionJéssica Castillo-Villalba, Raquel Gasque-Rubio, Lorena Forés-Toribio, et al.
Science Advances|October 9, 2024
AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of actionEstefanía Cerro-Herreros, Judit Núñez-Manchón, Neia Naldaiz-Gastesi, et al.
Molecular Therapy. Nucleic Acids|September 13, 2021
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophyEstefanía Cerro-Herreros, Irene González-Martínez, Nerea Moreno, et al.
Journal of Neurology|January 8, 2025
Clinical features, mutation spectrum and factors related to reaching molecular diagnosis in a cohort of patients with distal myopathiesNuria Muelas, Lidón Carretero-Vilarroig, Pilar Martí, et al.
Pageof 2